Business News • PR NewsWire • Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease

THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid...

View More : http://www.prnewswire.com/news-releases/treatment-with-enbrel-etanercept-shows-significant-and-sustained-clinical-benefi...

Releted News by prnewswire

MarketTools Showcases Mobile Research and Online Communities at The Market Research Event 2011, November 7-9

Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

Santaris Pharma A/S' Phase 2a forsøg med miravirsen i patienter inficeret med Hepatitis C viser efter fire ugers behandling en dosis-afhængig, langtidsvirkende virus reduktion med 2-3 logs i HCV RNA

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

In the Mood for Great Barbecue? Come to Dickey's Barbecue in Florida